Increased circulating levels of interleukin-6 induce perturbation in redox-regulated signaling cascades in muscle of dystrophic mice by Pelosi, Laura et al.
Research Article
Increased Circulating Levels of Interleukin-6 Induce
Perturbation in Redox-Regulated Signaling Cascades in
Muscle of Dystrophic Mice
Laura Pelosi,1 Laura Forcina,1 Carmine Nicoletti,1 Bianca Maria Scicchitano,2 and
Antonio Musarò1,3
1DAHFMO-Unit of Histology and Medical Embryology, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur
Italia-Fondazione Cenci Bolognetti, Rome, Italy
2Institute of Histology and Embryology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy
3Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy
Correspondence should be addressed to Antonio Musarò; antonio.musaro@uniroma1.it
Received 7 April 2017; Revised 31 May 2017; Accepted 7 June 2017; Published 6 August 2017
Academic Editor: Andrea Vasconsuelo
Copyright © 2017 Laura Pelosi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Duchenne muscular dystrophy (DMD) is an X-linked genetic disease in which dystrophin gene is mutated, resulting in
dysfunctional or absent dystrophin protein. The pathology of dystrophic muscle includes degeneration, necrosis with
inflammatory cell invasion, regeneration, and fibrous and fatty changes. Nevertheless, the mechanisms by which the absence of
dystrophin leads to muscle degeneration remain to be fully elucidated. An imbalance between oxidant and antioxidant systems
has been proposed as a secondary effect of DMD. However, the significance and precise extent of the perturbation in redox
signaling cascades is poorly understood. We report that mdx dystrophic mice are able to activate a compensatory antioxidant
response at the presymptomatic stage of the disease. In contrast, increased circulating levels of IL-6 perturb the redox signaling
cascade, even prior to the necrotic stage, leading to severe features and progressive nature of muscular dystrophy.
1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked
genetic disease caused by mutations in the dystrophin gene,
leading to instability of the dystrophin-glycoprotein complex
(DGC) with subsequent necrosis and fibrosis [1].
Although the genetic basis of DMD is known, the mech-
anisms by which the primary genetic defect leads to muscle
wasting remain to be fully elucidated [2–4]. Among the
potential factors involved in the pathogenesis of muscular
dystrophy, oxidative stress [5, 6] might be responsible for
the activation of degenerative processes and for the appear-
ance and progress of pathologic changes in dystrophic mus-
cles [4]. Nevertheless, the significance and precise role of
excessive oxidant-related damage is poorly understood. The
reactive oxygen species (ROS) are naturally and constantly
formed inside of the organism, as a result of cell activity. It
is plausible that under physiological conditions, skeletal mus-
cle activates an endogenous program of antioxidant defense
to maintain the ROS production at physiological levels [7].
Extreme or pathologic conditions generate much higher
levels of ROS that overwhelm cellular antioxidant defenses,
leading to protein carbonylation, DNA damage, and RNA
oxidation. The excess of ROS production can also alter cal-
cium handling, another pathogenic factor associated with
muscular dystrophy, leading to the activation of proteolytic
systems and muscle wasting [8, 9].
Different animal models of dystrophin deficiency are
actively studied. The mdx mouse is the most widely used
model for muscular dystrophy [2]. However, the mdx mouse
presents some limitations, including the pathophysiology
and clinical outcome criteria, compared to DMD patients,
due to the fact that skeletal muscles of mdx mice undergo
extensive necrosis only early in neonatal life. Thus, there is
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a greater imperative towards improving the validity of animal
models and the design of preclinical experimental therapeu-
tic approaches. We recently generated a more severe animal
model, the mdx/IL6 mouse, that closely approximates the
human disease and more faithfully recapitulates the disease
progression in humans [10]. In particular, we observed that
forced expression of IL-6 in the adult mdx mice, increased
necrosis, sustained inflammatory response, and repeated
cycles of muscle degeneration and regeneration, leading to
exhaustion of satellite cells [10].
In this study, we analysed whether the exacerbated
phenotype induced by increased circulating levels of IL-6
involves a perturbation in redox signaling cascade, even prior
to the necrotic phase. We revealed, in mdx/IL6 mice, a
progressive reduction of the Nrf2-dependent antioxidant
compensatory mechanism, a severe phenotypic feature
observed in human DMD patients [11].
2. Materials and Methods
2.1. Mice and Treatments. Animal models used in the current
study are 2-, 4-, and 24-week-old wild-type C57Bl/6J mice
and mdx (Jackson Laboratories) and mdx/IL6 [10] trans-
genic mice. moAb-IL6R treatment: mdx mice were
injected subcutaneously, starting at 15 days of age, with
the neutralizing monoclonal antibody MR16-1 (kindly
provided by Chugai Pharmaceutical Co., Ltd.) [3, 12] to
the murine IL-6 receptor (moAb-IL6R) at a dose of
100μg/g of body weight and then twice a week with
20μg/g (for a total of 5 doses) in PBS [3]. Mice were
sacrificed at 4 weeks of age. Animals were maintained
according to the institutional guidelines of the animal
facility of the unit of Histology and Medical Embryology.
All the animal experiments were approved by the ethics
committee of Sapienza University of Rome-Unit of Histol-
ogy and Medical Embryology and were performed in
accordance with the current version of the Italian law on
the protection of animals.
2.2. Protein Extraction andWestern Blot Analysis.Diaphragm
muscles were isolated from 2-, 4-, and 24-week-old mdx
and mdx/IL6 mice and immediately frozen in liquid nitro-
gen. Each sample (liquid nitrogen powdered diaphragm
muscles) was homogenized in protein lysis buffer [Tris-
HCl, pH 7.5/20mM, EDTA/2mM, EGTA/2mM, sucrose/
250mM, DTT/5mM, Triton-X/0.1%, PMSF/1mM, NaF/
10mM, SOV4/0.2mM, cocktail protease inhibitors/1X
(Sigma Aldrich)]. Western blotting analysis was performed
using 70μg of protein extracts, and filters were blotted with
antibodies against gp91phox (BD Transduction Laborato-
ries), Nrf2 (Santa Cruz Biotechnology), NFκB p65 (ser536;
Cell Signaling), NFκB (Cell Signaling), α-tubulin (Sigma
Aldrich), β-tubulin (Cell Signaling), Glu-tubulin (detyrosi-
nated α-tubulin; Abcam), and GAPDH (Santa Cruz Biotech-
nology). Signals derived from appropriate HRP-conjugated
secondary antibodies (Bethyl Laboratories) were captured
by Chemi DocTM XRS 2015 (Bio-Rad Laboratories), and
densitometric analysis was performed using Image Lab
software (version 5.2.1; Bio-Rad Laboratories©).
2.3. RNA Extraction and Quantitative Real-Time PCR
Analysis. The total mRNA of 2-, 4-, and 24-week-old wild-
type, mdx, and mdx/IL6 mice was extracted from liquid
nitrogen powdered diaphragm muscle in TRI Reagent
(Sigma-Aldrich) using Tyssue Lyser (Qiagen). To synthesize
double-stranded cDNA, 1μg of each RNA sample was
reverse transcribed using the QuantiTect Reverse Transcrip-
tion kit (Qiagen). For the analysis of IL-6, TNFα, IL-1β, IL-
10, and IL6rα, cDNA from each sample was preamplified
using the TaqMan PreAmp Master Mix (Applied Biosystem)
according to the manufacturer’s protocol. Quantitative real-
time PCR was performed, with or without preamplification
procedure, on ABI PRISM 7500 SDS (Applied Biosystem)
using specific 6-carboxyfluorescein (FAM)-labeled TaqMan
assays for SIRT1, Utrn, SOD1, SOD2, CAT-1, Gpx1, GCLC,
GCLM, NQO1, HO-1, IL-6, TNFα, IL-1β, IL-10, IL6rα, and
Hprt as housekeeping genes (Applied Biosystem). Data were
analysed using the 2-DDCt method and reported as mean
fold change in gene expression relative to wild type.
2.4. Dihydroethidium Staining and Confocal Analysis for ROS
Detection. Muscles from wild-type, mdx, mdx/IL-6, and
mdx-treated mice with the neutralizing monoclonal antibody
to the IL-6 receptor (moAb-IL6R) were embedded in tis-
sue freezing medium and snap frozen in nitrogen-cooled
isopentane. Muscle frozen sections (30μm) were incubated
with 5μM dihydroethidium (DHE) (Molecular Probes;
#D23107) in PBS at 37°C for 30min [13] and analysed
at confocal microscopy (Laser-Scanning TCS SP2; Leica)
to reveal ROS production. DHE fluorescence was analysed
with LAS AF Lite software, measuring the total intensity
of DHE fluorescence, which represents the full amount
of fluorescence held within the entire z-axis of the series.
60 optical sections/genotype for three separate experiments
were analysed.
2.5. Data and Statistical Analysis. Statistical analysis was per-
formed using the GraphPad Prism software (San Diego, CA,
USA). Statistically significant differences among groups were
assessed using one-way ANOVA with a Bonferroni’s posttest
or Dunn’s posttest and between pairs with Mann–Whitney
test or Student’s t-test for normally distributed variables.
All data are presented as mean± SEM; p < 0 05 is considered
statistically significant. Sample size was predetermined based
on the variability observed in preliminary and similar exper-
iments. All experiments requiring animal models were sub-
jected to randomization based on litter.
3. Results
3.1. Increased Levels of IL-6 Cytokine Contribute to Enhance
Markers of ROS Production in mdx Mouse Model. The prog-
ress of the dystropathology in the mdx mouse model has
been extensively described. A prenecrotic stage, characterized
by normal myofibres with peripheral nuclei, intact sarco-
lemma, and nonfragmented sarcoplasm, is observed within
the first 21 days of age. Necrosis peaks by 25-26 days and
then significantly decreases to stabilize by 8 weeks of age to
a relatively low level of active damage [2]. Among the
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secondary processes that accompany muscle degeneration,
the infiltration of inflammatory cells reflects the immune
response to tissue damage.
To verify whether oxidative stress is a direct consequence
of necrosis and inflammation or whether it can be induced in
the prenecrotic stage, we analysed relevant markers of the
redox signaling in the muscle of 2-week-old mdx mice. We
found a strong upregulation of gp91phox (NOX2), the main
source of ROS production [14, 15], in the diaphragm of 2-
week-old mdx mice compared to wild-type littermates
(Figure 1(a)), suggesting the presence of pro-oxidant condi-
tions during the early disease stages. This was supported by
a significant reduction in SIRT1 and Nrf2 expressions
(Figures 1(b) and 1(c)), which are important mediators that
promote the antioxidant response by activating several anti-
oxidant enzymes [16–20].
It has been reported that, although with the absence of
significant infiltration of mononuclear inflammatory cells
within the dystrophic muscle, DMD patients display an
increase in the plasma levels of proinflammatory cytokines
at the presymptomatic stage of the disease [21]. Thus, the
release of specific proinflammatory cytokines can stimulate
ROS production, enhancing cellular damage in DMD [22].
To support this evidence, we analysed relevant markers of
the oxidant and antioxidant signaling in the muscle of
mdx/IL6 mice [10] at the prenecrotic stage. Increased IL-6
plasma levels induced a strong upregulation of gp91phox
expression (Figure 1(a)) accompanied by a significant down-
regulation of SIRT1 and Nrf2 expressions (Figures 1(b) and
1(c)) in 2-week-old mdx/IL6 mice, compared to both wild-
type and mdx littermates. This suggests that IL-6 promotes
a perturbation of redox status in dystrophic muscles, modu-
lating relevant factors of the redox signaling even in the
prenecrotic phase.
To casually link IL-6 overexpression with ROS produc-
tion in DMD pathology, we treated 2-week-old mdx mice
with the neutralizing monoclonal antibody to the IL-6 recep-
tor (moAb-IL6R), as previously described [3]. Fifteen days
after the treatment, we analysed the ROS-sensitive dye
DHE in the muscle of untreated and moAb-IL6R-treated
mdxmice. Figure 1(d) shows a strong reduction of DHE fluo-
rescence in moAb-IL6R-treated mdx compared to untreated
mdx mice, indicating that IL-6 blockade prevents excessive
ROS production in dystrophic muscles. Notably, the muscle
of mdx/IL6 mice displayed a significant increase of DHE
fluorescence compared to that of control mdx and moAb-
IL6R-treated mdx littermates (Figure 1(d)), supporting the
role of IL-6 in the induction of pathologic changes observed
at prenecrotic stage.
Overexpression of utrophin (Utrn) is able to counteract
the lack of dystrophin protecting the sarcolemma integrity
in the dystrophic muscle [23, 24]. Thus, we evaluated the
levels of Utrn mRNA in the diaphragm of 2-week-old wild-
type, mdx, and mdx/IL6 mice and we found a significant
upregulation of its expression in mdx mice, compared to
both wild-type andmdx/IL6 mice (Figure 1(e)). Interestingly,
IL-6 overexpression reduced Utrn expression compared to
mdx littermates, further supporting the evidence that the
mdx/IL6 mouse model closely approximates the human
disease and more faithfully recapitulates the disease progres-
sion in humans.
3.2. Analysis of Nrf2 Antioxidant Genes in Muscle of
Dystrophic Mice at Prenecrotic Stage. We have recently
reported the central role of Nrf2 signaling pathway in the
pathogenesis of DMD [11]. To better define the Nrf2-
dependent antioxidant response in the prenecrotic dystro-
phic muscle, we analysed the expression of Nrf2 antioxidant
enzymes in 2-week-old mdx mice (Figure 2). We found
that the levels of several Nrf2-regulated gene expressions
including SOD1/2, CAT-1, Gpx1, and GCL [25] were
expressed at similar levels in both 2-week-old wild-type
and mdx mice, whereas NAD(P)H quinone dehydrogenase
1 (NQO1), the enzyme catalyzing the reduction of qui-
nones to hydroquinones, was reduced in mdx mice com-
pared to wild-type littermates (Figure 2(a)). Of note,
ROS-detoxifying enzymes, such as catalase-1 and Gpx1,
were significantly reduced in mdx/IL6 compared to mdx
mice, being consistent with the reduction in Nrf2 protein
level (Figure 1(c)).
Interestingly, HO-1, another Nrf2-regulated gene and a
modulator of the inflammatory response, was upregulated
in both mdx and mdx/IL6 mice compared to wild-type litter-
mates, although the expression of HO-1 resulted reduced in
mdx/IL6 mice compared to mdx littermates (Figure 2(b)).
It is plausible that the initial increase in IL-6 plasma levels
induces an alteration in the redox signaling, which might
stimulate the inflammatory response. To support this
hypothesis, we analysed the expression of both proinflam-
matory cytokines such as IL-6, TNFα, and IL-1β and
anti-inflammatory cytokine, such as IL-10, in 2-week-old
dystrophic mice (Figures 2(c), 2(d), 2(e), and 2(f)). We
found that increased plasma levels of IL-6 induced an
upregulation of relevant markers of muscle wasting, such
as IL6Rα (Figure 2(g)), IL-1β (Figure 2(e)), TNFα
(Figure 2(d)), and NFκB (Figure 2(h)) [26, 27] in mdx/
IL6 mice, compared to mdx littermates. This suggests that
IL-6 triggers an alteration in the redox signaling, initiating
degenerative process [22, 26, 27].
3.3. X-ROS Signaling Is Altered in Prenecrotic Dystrophic
Diaphragm Muscle and Increases during the Progression of
Pathology. In DMD, the primary defect leads to the alteration
of microtubule network (MT network) that activates robust
NOX2-dependent ROS production, a pathway called X-
ROS [28]. A complete transcriptome analysis on biopsies of
DMD patients has also revealed an upregulation of several
X-ROS-related transcripts, including NOX2 and nine differ-
ent tubulin isoforms [28]. Moreover, genetic silencing of
Nrf2 enhances X-ROS signaling in a mild mouse model of
DMD [29], suggesting a correlation between X-ROS
signaling and Nrf2-dependent antioxidant response. The
upregulation of NOX2’s catalytic (gp91phox) subunit,
which we observed in the prenecrotic dystrophic muscle
(Figure 1(b)), suggests the presence of pro-oxidant condi-
tions that could be dependent by the alteration of X-
ROS signaling.
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Figure 1: Analysis of redox-regulating signaling in the diaphragm muscle of 2-week-old dystrophic mice. Western blot analysis (right panels
show representative images) for the expression of gp91phox (a) and Nrf2 (c) proteins in 2-week-old wild-type (WT), mdx, and mdx/IL6 mice.
Values represent mean± SEM; n = 3 to 6 mice per group. ∗p < 0 05, ∗∗p < 0 005, and ∗∗∗p < 0 0005 compared to WT mice; #p < 0 05 between
mdx and mdx/IL6 littermates by ANOVA. Real-time PCR analysis performed on diaphragm muscles fromWT, mdx, and mdx/IL6 mice at 2
weeks of age for the expression of SIRT1 (b) and utrophin (Utrn) (e). Values are reported as fold change in expression and represent
mean± SEM; n = 4 to 12 per group. ∗p < 0 05, ∗∗p < 0 005 compared to WT mice; #p < 0 05 (by ANOVA). (d) Blockade of IL-6 receptor
by moAb-IL6R neutralizing antibody reduces the amount of DHE-derived fluorescence in treated mdx compared to untreated mdx
mice. Graphs (left panel) show the quantification of DHE total intensity in the muscles of indicated genotypes. The right panel
shows representative images of DHE staining from the muscle sections of 4-week-old mdx/IL-6 and moAb-IL6R-treated and
untreated mdx mice. Scale bar, 100 μm. Values represent mean± SEM; n = 3 independent experiments. ∗∗∗∗p < 0 0001, ##p < 0 005
using ANOVA. In (a) and (c), the lanes were run on the same gel but were not contiguous.
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To support this hypothesis, we analysed the density of
MT network in terms of the abundance of α-, β-, and Glu-
tubulin proteins, in dystrophic muscles at 2 weeks of age
(Figures 3(a), 3(b), and 3(c)). We found an upregulation of
the overall subunits in mdx and mdx/IL6 compared to wild
type mice, indicating an alteration of microtubule network
at this stage of pathology. Notably, we observed a significant
increase in detyrosination of tubulin content (Glu-tubulin),
but not of the α (Figure 3(a))- and β (Figure 3(b))-tubulin
subunits, in the diaphragm of mdx/IL6 mice compared to
mdx littermates (Figure 3(c)).
To verify whether ROS production parallels X-ROS
signaling during the progression of DMD pathology, we
analysed gp91phox expression and microtubule subunits’
content in dystrophic mice at 4 and 24 weeks of age
(Figures 3(d) and 3(e)). We found that the dystrophic
muscle displayed per se increased levels of gp91phox and
tubulin subunit expression at both 4 (Figure 3(d)) and
24 weeks of age (Figure 3(e)) compared to wild type,
whereas increased levels of IL-6 significantly enhanced con-
tent of gp91phox and of α-, β-, and Glu-tubulin proteins
compared to mdx mice, suggesting that IL-6 exacerbates
the dystrophic phenotype acting also on the stimulation of
X-ROS signaling.
3.4. Increased Levels of IL-6 Affect Nrf2 Antioxidant Response
during the Progression of Pathology. In order to evaluate the
correlation between the temporal progression of X-ROS
signaling and Nrf2-dependent antioxidant response in
muscular dystrophy and to better define the pathogenic
role of IL-6 in muscular dystrophy, we analysed the
Nrf2-mediated antioxidant enzyme expression in the dia-
phragm of mdx and mdx/IL6 mice at different stages of
pathology (Figure 4). In particular, we evaluated the antioxi-
dant response in dystrophic mice at two different ages and
stages of disease, namely, at 4 weeks of age, in which a peak
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Figure 2: Nrf2 antioxidant genes are differently regulated in the prenecrotic dystrophic muscle. (a) Real-time PCR analysis of Nrf2-
dependent genes (SOD1, SOD2, CAT-1, Gpx1, GCL, and NQO1) performed on the diaphragm muscle of 2-week-old WT, mdx, and mdx/
IL6 mice. Values are reported as fold change in expression relative to the calibrator (WT, horizontal dot line) and represent mean± SEM;
n = 3 to 5 per group. p value by unpaired statistical tests. ^p < 0 05, ^^p < 0 005. Analysis of HO-1 mRNA (b), IL-6 mRNA (c), TNFα
mRNA (d), IL-1β mRNA (e), IL-10 mRNA (f), and IL6rα mRNA (g) expressions in the diaphragm of 2-week-old WT, mdx, and mdx/IL6
mice. Data are presented as the mean± SEM; n = 3 to 6 mice per group. ∗p < 0 05, ∗∗p < 0 005, and ∗∗∗p < 0 0005 compared to WT
mice; #p < 0 05, ##p < 0 005 between mdx and mdx/IL6 littermates (by ANOVA). (h) Densitometric analysis (left panel) and representative
western blot (right panel) for NFκB active (NFκB p65) and total (NFκB TOT) protein expression in the diaphragm muscle of indicated
genotypes. Values are reported as mean± SEM; n = 5 to 7 per group. p using Student’s two-tailed t-test. In (h), gels were simultaneously
run under same experimental conditions.
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of necrosis is observed, and at 24weeks of age, a stage in which
the affected muscle rapidly regenerates and regains structural
and functional integrity [2].
We found that most of the antioxidant enzymes, includ-
ing CAT-1, Gpx1, and GCL, were upregulated in 4-week-old
mdx and mdx/IL6 mice compared to wild-type littermates
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Figure 3: X-ROS signaling is altered in the prenecrotic dystrophic diaphragm muscle and increased during the progression of pathology.
Densitometric analysis (upper panels) and representative images (bottom panels) of western blot analysis for the expression of α-tubulin
(a), β-tubulin (b), and Glu-tubulin (c) proteins in the diaphragm muscle of 2-week-old WT, mdx, and mdx/IL6 mice. Values represent
mean± SEM; n = 3 to 7 mice per group. p value by ANOVA. X-ROS signaling components were analysed by western blot (left panels
show representative images) at later stages of pathology in 4-week-old (d) and 24-week-old (e) diaphragm muscle from WT, mdx, and
mdx/IL6 mice. Values are reported as protein content relative to age-matched WT (horizontal dot line) and represent mean± SEM; n = 3
to 7 mice per group. ^p < 0 05, ^^p < 0 005, and ^^^p < 0 0005 compared to WT mice; ∗p < 0 05, ∗∗p < 0 005 with respect to mdx
littermates (by ANOVA). Temporal progression of gp91phox (f), α-tubulin (g), β-tubulin (h), and Glu-tubulin (i) proteins between 4
weeks (4 w) and 24 weeks (24w) of age in the diaphragm muscles of indicated genotypes. Graphs show an increase of the expression levels
of tubulin subunits and of gp91phox protein during the progression of pathology. Values represent mean± SEM. ∗p < 0 05, ∗∗p < 0 005,
and ∗∗∗∗p < 0 0001 by ANOVA.
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(Figure 4(a)). Notably, the increased plasma levels of IL-6
induced a more significant upregulation of CAT-1 com-
pared to mdx mice (Figure 4(a)). We also found that the
levels of mRNAs that encode the components of gamma-
glutamyl-cysteine ligase and the rate-limiting enzyme for
glutathione biosynthesis (glutamyl-cysteine ligase modula-
tor (GCLM) and glutamyl-cysteine ligase catalytic subunit
(GCLC)) were expressed at higher levels in mdx/IL6 mice
compared to mdx littermates, indicating that IL-6 overex-
pression induces a dysregulation of GSH synthesis in dys-
trophic muscles. These data suggest that the exacerbated
muscle phenotype, induced by increased levels of IL-6 is
associated with an imbalance between oxidant and antiox-
idant systems, as also suggested by increased expression of
Nrf2 protein in 4-week-old mdx/IL6 mice compared to
mdx littermates (Figure 4(b)).
Then, we analysed the expression pattern of the antioxi-
dant enzymes in both mdx and mdx/IL6 mice of 24 weeks
of age, a stage normally spared by the absence of dystrophin.
We observed that CAT-1 and Gpx1, which catalyze the
conversion of hydrogen peroxide to water and oxygen, were
still upregulated in the diaphragm of 24-week-old mdx mice
compared to both wild-type and mdx/IL6 mice (Figure 4(c)).
This suggests that the antioxidant compensatory mechanism
is still activated in adult mdx muscles and this might explain
the mild muscle phenotype observed in mdx mice at
this stage of pathology. In contrast, increased levels of
IL-6 induced a significant downregulation of the ROS-
detoxifying enzymes, compared to mdx mice, suggesting
that IL-6 overexpression negatively affects the compensatory
response in the dystrophic muscle. This evidence was
supported by the significant reduction of Nrf2 protein
expression in 24-week-old mdx/IL6 mice compared to mdx
littermates (Figure 4(d)).
4. Discussion
In this study, we monitored relevant markers of the redox
signaling in the dystrophic muscle and suggested a poten-
tial link between increased circulating levels of IL-6 and
oxidative damage.
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Figure 4: Time course analysis of Nrf2-dependent antioxidant response in dystrophic mice. Real-time PCR analysis performed on diaphragm
muscles from wild-type (WT), mdx, and mdx/IL6 mice at 4 (a) and 24 (c) weeks of age for the expression of Nrf2-dependent genes involved in
the antioxidant response. Values are reported as fold change in the expression relative to the calibrator (WT, horizontal dot line) and
represent mean± SEM; n = 3 to 6 mice per group. ^p < 0 05, ^^p < 0 005 compared to WT mice; ∗p < 0 05, ∗∗p < 0 005 with respect to mdx
littermates (by ANOVA). Nrf2 protein expression was evaluated by western blot analysis (right panels show representative images) in 4-
week-old (b) and 24-week-old (d) diaphragms of indicated genotypes. Densitometric analyses (left panels) are expressed as values relative
to age-matched mdx and represent mean± SEM; n = 4 to 5 mice per group. p value using Student’s two-tailed t-test.
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Duchenne muscular dystrophy is an X-linked genetic
disease due to mutations in the dystrophin gene, leading to
alterations in intracellular signaling that causes an imbalance
between protein synthesis and protein degradation, with
subsequent necrosis and fibrosis [1].
Currently, there is no effective therapy for Duchenne
muscular dystrophy. Although stem cells and exon skip-
ping approach offer new tools for regeneration in muscle
disease, the signaling and molecular pathway involved in
the survival of the rescued phenotype is an important
question that remains to be satisfactorily addressed. Among
factors that might interfere with therapeutic approaches,
the dystrophic environment represents an important deter-
minant [30]. Thus, a better understanding of the hostile
microenvironment should prove useful for producing new
adjuvant treatments.
Potential candidates that contribute to sustain a hos-
tile microenvironment in the dystrophic muscle include
oxidative stress [4] and interleukin-6 (IL-6), a pleiotropic
cytokine that is produced by different cell types and has
the capacity to induce several different intracellular signaling
pathways [3, 10, 31]. The skeletal muscle is able to activate,
under physiological conditions, an endogenous program of
antioxidant defense to maintain the ROS production at a
functional level [7]. Nevertheless, damaging stimuli might
alter the delicate balance between ROS production and anti-
oxidant defense, leading to oxidative stress. The opposite
effects exerted by different concentration of ROS can be jus-
tified considering the concept of hormesis [32], in which a
low dose of a substance is stimulatory and a high dose is
inhibitory. Thus, the muscle benefits from low doses of
radicals while it is damaged by higher levels of ROS.
Our work supports the evidence that dystrophic mus-
cle is able to activate a compensatory response to cope
the negative effects of oxidative stress. Nevertheless, this
compensatory mechanism is impinged by factors that
are associated with the pathogenesis of muscular dystro-
phy, such as IL-6. Indeed, the persistent activation of
IL-6 signaling impairs the antioxidant response during
the progression of pathology, contributing to the severity
of pathology.
In particular, we first verified whether relevant markers
of the redox signaling are direct targets of necrosis and
inflammation, which characterize the necrotic stage of the
disease, or whether they can be induced in the prenecrotic
stage. We found a strong upregulation of one of the relevant
and critical factors for ROS production in the dystrophic
muscle, namely, gp91phox (NOX2), and a significant reduc-
tion in SIRT1 and Nrf2 expression, important mediators of
the antioxidant response, in the diaphragm muscle of 2-
week-old mdx mice compared to wild-type littermates. This
indicates that the activation of redox-regulated signaling pre-
cedes necrosis rather than resulting from it and supports oxi-
dative stress as a primary pathogenetic mechanism in
muscular dystrophy [4].
We also analysed the relevant markers of the X-ROS
signaling at 4 weeks (necrotic stage) and 24 weeks (a stage
normally spared by the absence of dystrophin) of age in
mdx mice. We revealed that X-ROS signaling is already
altered in the dystrophic diaphragm at the necrotic stage,
whereas markers of the antioxidant compensatory mecha-
nism were upregulated in adult mdx muscles.
To further support the evidence that the imbalance
between oxidant and antioxidant mechanisms is a patho-
genic factor associated with the severity of pathology, we
analysed the markers of X-ROS signaling in the dia-
phragm muscle of mdx/IL6 mouse model, which recapitu-
lates the severe phenotypic characteristics of DMD in
NF휅B
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Nrf2
IL-1훽
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Figure 5: IL-6 exacerbates the oxidant-related damage in the dystrophic muscle. Increased levels of IL-6 could contribute to amplify
degenerative processes in mdxmice by enhancing the expression of both gp91phox and NFκB and by reducing the Nrf2-antioxidant response.
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humans [3, 10]. Sustained increase in the levels of IL-6
alone is sufficient to exacerbate the dystrophic phenotype
at a stage, 24 weeks of age, when only a mild muscle phe-
notype is apparent in mdx mice [10]. We revealed that
increased levels of IL-6 induced a significant downregula-
tion of the ROS-detoxifying enzymes, compared to mdx
mice, and negatively affect the compensatory response in
the dystrophic muscle.
5. Conclusion
Overall, our study is consistent with the model in which
IL-6 could act as an important player in the crosstalk
between ROS production and inflammatory response
[22]. Increased levels of IL-6 enhance the expression of
both gp91phox and NFκB and impinge the Nrf2-
dependent antioxidant response in the dystrophic muscle,
even at the prenecrotic stage (Figure 5). This altered redox-
regulated signaling might trigger an inflammatory response,
leading to muscle wasting.
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